文献速递类风湿关节炎

临床缓解期RA患者结构损伤进展的临床与超声生物标志物:12个月前瞻性研究

Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
PubMed 文献 · Semin Arthritis Rheum · 2017-05-01

本研究纳入DAS28-ESR<2.6持续>6个月的临床缓解期RA患者,基线与12个月时行双手双膝超声及优势手MRI,42例完成随访。基线MRI侵蚀评分、BMI、病程、泼尼松治疗、未用生物制剂及csDMARDs、超声活动性滑膜炎(UdAS)与12个月MRI侵蚀评分进展显著相关;探索性分析中血清钙卫蛋白与骨水肿进展相关。

要点

  • 基线超声活动性滑膜炎(同时具备滑膜增生与PD信号)与12个月MRI侵蚀进展相关。
  • 基线MRI侵蚀评分、BMI、病程、泼尼松治疗及未用生物/传统合成DMARDs亦与侵蚀进展相关。
  • 探索性分析提示血清钙卫蛋白与骨水肿进展相关。

核心结论

  • 临床缓解期RA患者中,基线超声活动性滑膜炎(滑膜增生+PD信号)与12个月MRI侵蚀进展相关。
  • 基线MRI侵蚀评分、BMI、病程、泼尼松治疗及未用生物制剂和csDMARDs与12个月MRI侵蚀评分进展相关。
  • 探索性分析中血清钙卫蛋白与骨水肿进展相关。

研究设计与样本

  • 前瞻性研究,纳入DAS28-ESR<2.6持续>6个月的临床缓解期RA患者55例,42例完成12个月随访。
  • 基线与12个月时行双手双膝超声及优势手MRI,随访12个月。

主要发现

  • 42例完成随访者中78%为女性,年龄中位数54岁,病程93个月。
  • 基线时12例(28%)口服泼尼松,34例(81%)用csDMARDs,20例(47%)用生物制剂。
  • 基线时45%符合既往定义的超声活动性滑膜炎(UdAS)标准(PD信号+滑膜增生≥2)。
  • 多因素分析显示基线MRI侵蚀评分、BMI、病程、泼尼松治疗、未用生物制剂及csDMARDs、UdAS与12个月MRI侵蚀评分进展显著相关。
  • 探索性分析中血清钙卫蛋白水平与骨水肿进展显著相关。

关键数值与推荐

  • 临床缓解定义为DAS28-ESR<2.6持续>6个月。
  • 超声活动性滑膜炎(UdAS)定义为PD信号+滑膜增生≥2。

临床怎么用

  • 对临床缓解期RA患者,可评估超声活动性滑膜炎(滑膜增生+PD信号)以识别结构损伤进展风险较高者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine clinical and sonographic biomarkers predicting structural damage progression at 12 months of follow-up as measured by magnetic resonance imaging (MRI) in rheumatoid arthritis (RA) patients in clinical remission. PATIENTS AND METHODS: We included patients with RA in clinical remission, defined as 28-joint disease activity score (DAS28)-erythrocyte sedimentation rate (ESR) <2.6 for >6 months. Ultrasound scans of both hands and knees and MRI of the dominant hand were performed at baseline and at 12 months. RESULTS: Out of 55 patients, 42 completed the follow-up. Among them, 78% were female, aged (median) 54 years; disease duration was 93 months. In total, 12 (28%) patients were taking oral prednisone, 34 (81%) conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and 20 (47%) biological therapies. At baseline, 45% fulfilled criteria previously defined for ultrasound-defined active synovitis (UdAS) [PD (power Doppler) signal + synovial hyperplasia ≥2]. Multivariate analysis showed significant associations between baseline MRI erosion score, body mass index (BMI), disease duration, prednisone treatment, absence of biologic and csDMARDs, UdAS, and MRI erosion score progression after 12 months. In an exploratory analysis, serum levels of calprotectin correlated significantly with bone edema progression. CONCLUSIONS: We identified clinical and sonographic markers of structural damage progression after 12 months follow-up in patients with RA in clinical remission. Meeting the criteria of ultrasound active synovitis, defined as simultaneous relevant synovial hyperplasia and PD, was associated with erosion progression after 12 months. Calprotectin was associated with bone edema, in an exploratory analysis.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ramírez J, Narváez JA, Ruiz-Esquide V, et al. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up. Semin Arthritis Rheum. 2017. PMID: 28549731. doi:10.1016/j.semarthrit.2017.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。